Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne

Late-breaking Presentation by Dr. Adelaide Hebert at 2018 AAD Annual Meeting

Novan, Inc. today announced that data from the Company’s two Phase 3 clinical trials and long-term safety trial with SB204 for the treatment acne vulgaris will be presented during a Late-breaking Research forum at the 2018 Annual Meeting of the American Academy of Dermatology, or AAD, in San Diego, California.

Read the full press releaseCompany website